Shares of BELLUS Health Inc. (TSE:BLU – Get Free Report) fell 0.1% on Monday . The company traded as low as C$19.24 and last traded at C$19.48. 28,666 shares changed hands during mid-day trading, a decline of 52% from the average session volume of 59,471 shares. The stock had previously closed at C$19.50.
BELLUS Health Stock Down 0.1 %
The firm has a market capitalization of C$2.47 billion, a PE ratio of -20.29 and a beta of -0.28. The business’s 50 day moving average is C$19.48. The company has a debt-to-equity ratio of 0.32, a current ratio of 33.42 and a quick ratio of 16.40.
About BELLUS Health
BELLUS Health Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus.
Recommended Stories
- Five stocks we like better than BELLUS Health
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Intel: Is Now the Time to Be Brave?
- The Risks of Owning Bonds
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Where Do I Find 52-Week Highs and Lows?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with MarketBeat.com's FREE daily email newsletter.
